Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 22Stomach Neoplasms 19Ovarian Neoplasms 18Colorectal Neoplasms 18Melanoma 15Carcinoma, Hepatocellular 15Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Neoplasm Metastasis 10Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Liver Neoplasms 7Head and Neck Neoplasms 7Anus Neoplasms 7Colonic Neoplasms 6Carcinoma, Renal Cell 6Vaginal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Penile Neoplasms 5Neoplasms 5Mesothelioma 5Lung Neoplasms 5Cholangiocarcinoma 5Triple Negative Breast Neoplasms 4Oropharyngeal Neoplasms 4Neuroblastoma 4Gastrointestinal Neoplasms 4Carcinoma, Merkel Cell 4Vulvar Neoplasms 3Urinary Bladder Neoplasms 3

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1aldesleukin 1Thalidomide 1Radiotherapy, Image-Guided 1Psychiatric Rehabilitation 1Fentanyl 1Docetaxel 1Cyclophosphamide 1Bariatric Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × fludarabine × Gastrointestinal × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡